Risk factors and determinants of carotid intima-media thickness in children: protocol for a systematic review and meta-analysis.
Fiche du document
4 juin 2018
- doi: 10.1136/bmjopen-2017-019644
- issn: 2044-6055
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1136/bmjopen-2017-019644
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/29866720
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2044-6055
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_6026FC2F9B077
info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/
Citer ce document
A.M. Epure et al., « Risk factors and determinants of carotid intima-media thickness in children: protocol for a systematic review and meta-analysis. », Serveur académique Lausannois, ID : 10.1136/bmjopen-2017-019644
Métriques
Partage / Export
Résumé
Carotid intima-media thickness (CIMT) is a surrogate marker of atherosclerosis that is measured in adults and children to better understand the natural history of cardiovascular disease (CVD). In adults, CIMT is predictive of myocardial infarction and stroke. In children and adolescents, CIMT is used to assess vascular changes in the presence of CVD risk factors (obesity, hypertension, smoking, etc) or clinical conditions associated with a high risk for premature CVD. However, there is no comprehensive overview, in a life-course epidemiology perspective, of the risk factors and determinants of CIMT in children. It is also important to evaluate between-study differences in CIMT measurement methods and take them into consideration when drawing conclusions. Our objective is to systematically review the evidence on the relationship between CIMT and prenatal and postnatal exposures or interventions in children, as well as documenting and discussing the CIMT measurement methods. Systematic searches of the Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica (EMBASE)and Central Register of Controlled Trials (CENTRAL) databases will be conducted. The reference lists and other literatures sources will be browsed. Observational and experimental studies in children from birth up to 18 years will be included. Prenatal and postnatal exposures or interventions assessed in relationship with CIMT will be considered for inclusion. Examples might include gestational age, obesity, hypertension, tobacco exposure, specific at-risk conditions (chronic kidney disease, diabetes, etc) or statin treatment. The outcome will be CIMT assessed by ultrasonography. The setting, scanning and measurement methods for each included study will be described in detail. Results will be synthesised descriptively and, if appropriate, will be pooled across studies to perform meta-analyses. Separate meta-analyses for each exposure or intervention type will be conducted. This systematic review will be published in a peer-reviewed journal. A report will be prepared for clinicians and other healthcare decision-makers. CRD42017075169.